Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2025; 17(8): 109093
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.109093
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.109093
Hepatic osteodystrophy: An underrecognized metabolic bone disease
Subhodip Pramanik, Department of Endocrinology, Neotia Getwel Healthcare Centre, Siliguri 734010, West Bengal, India
Rajan Palui, Department of Endocrinology, The Mission Hospital, Durgapur 713212, India
Sayantan Ray, Department of Endocrinology, All India Institute of Medical Sciences, Bhub
Author contributions: Pramanik S performed the literature search, wrote the first draft and provided intellectual input; Palui R and Ras S conceptualized the work, performed a literature search, supervised the writing, provided intellectual input and critically revised the manuscript; Ray S supervised the literature search, the writing, provided intellectual input and critically revised the manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sayantan Ray, Assistant Professor, Department of Endocrinology, All India Institute of Medical Sciences, Sijua, Patrapada, Bhubaneswar 751019, India.
Received: April 29, 2025
Revised: June 10, 2025
Accepted: July 8, 2025
Published online: August 27, 2025
Processing time: 120 Days and 14.2 Hours
Revised: June 10, 2025
Accepted: July 8, 2025
Published online: August 27, 2025
Processing time: 120 Days and 14.2 Hours
Core Tip
Core Tip: Hepatic osteodystrophy (HO) is a common complication, manifested as osteoporosis or osteopenia, encountered in the evolution of chronic liver diseases (CLD). Despite being clinically significant, it often represents an underappreciated and underdiagnosed complication of CLD as systematic screening and management remain suboptimal. The general biology of HO, including its pathogenesis, diagnostic tools, and rationale for treatment, has been determined largely empirically from studies of postmenopausal women with osteoporosis. The treatment of HO is limited, reflecting an unmet need for the best possible management of this disorder. Bisphosphonates have been shown to be effective in selected group of patients with CLD.